The increasing incidence of liver disorders and rare metabolic diseases such as urea cycle disorders is driving demand for hyperammonemia treatments, but the market also faces several challenges. High treatment costs, delayed diagnosis of rare genetic disorders, and limited availability of specialized therapies can hinder timely patient care. In addition, stringent regulatory requirements, the...